Cho Wook-je, CEO of Yuhan Corporation, expressed his aspiration during the company’s New Year ceremony on Feb. 2, saying, "We will create results early through selection and concentration on core tasks such as new drug development."
In his New Year’s address, Cho said, "Last year was a management environment that was more difficult and uncertain than ever, including the global situation." He added, "I sincerely thank all employees for their wholehearted efforts in their respective positions during such times." He reflected on the company’s achievements, including the launch of ‘Lecraza,’ which obtained U.S. Food and Drug Administration (FDA) approval as the first domestically produced antitumor drug, and said the company achieved sustainable growth.
Cho noted, "This year’s management environment is expected to be difficult, as a perfect storm, or economic hybrid crisis, is anticipated. However, with a mindset of 'Gae Sin Chang Rae' (開新創來), let’s overcome uncertainty and create new paths, turning crises into opportunities for even greater growth."
He further emphasized, "As we are on the verge of our 100th anniversary, we will achieve the goals set by each division based on a strong sense of responsibility and differentiated strategies to enter the list of the world’s top 50 pharmaceutical companies, our long-term goal."
Additionally, he stressed, "We will establish a virtuous cycle structure by stabilizing revenue structures and creating early results through selection and concentration on core tasks such as new drug development, and reinvesting the secured resources into research and development."